Navigation Links
New Non-Drowsy CLARITIN(R) 12-Hour Gets Allergy Sufferers Through Their Busy Day
Date:9/1/2009

KENILWORTH, N.J., Sept. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced the introduction of CLARITIN 12-Hour, the only 12-hour allergy medicine found in the allergy aisle. New CLARITIN 12-Hour lasts all day and provides effective, non-drowsy relief from the worst indoor and outdoor allergy symptoms. The product is available for adults and children ages six and up.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090901/NY68186)

"New CLARITIN 12-Hour offers the proven allergy relief people have relied on for years, with the added flexibility for people who want more control of their treatment," said Dr. John O'Mullane, group vice president, research and development, Schering-Plough Consumer Health Care. "Allergy sufferers can choose to treat their allergy symptoms for 12 or 24 hours depending on their individual needs."

Until now, sufferers shopping the allergy aisle had to choose between 4-6 hour products, which could cause drowsiness, or products offering 24 hours of relief. However, according to a recent study, 34% of allergy sufferers want something in between (1). Today, those sufferers finally have a non-drowsy option that meets their needs.

CLARITIN 12-Hour, which comes in convenient RediTabs(R) tablets, is great for people on the go since they dissolve quickly without water (2). It is also convenient for moms looking to give their kids all day allergy relief, while allowing the flexibility to re-dose at night, if needed.

Like other CLARITIN products, NEW CLARITIN 12-Hour is available without a prescription and treats allergy symptoms such as itchy, watery eyes, sneezing, and runny nose without drowsiness. CLARITIN 12-Hour can be found in most food, drug or mass retailers.

(1) 2007 Millward Brown Study

(2) Speed of dissolution does not imply speed of relief.

About CLARITIN

All CLARITIN(R) brand products are non-drowsy and available without a prescription. CLARITIN provides powerful allergy relief for 12 or 24 hours and comes in a variety of forms, including: CLARITIN Tablets, CLARITIN(R) Liqui-Gels(R), an easy-to-swallow liquid-filled capsule, and CLARITIN RediTabs tablets, a quickly dissolving tablet for ages 6 and older. And now, CLARITIN 12-Hour RediTabs provide the flexibility to manage allergy symptoms all day or all night.

CLARITIN-D(R) is available behind-the-counter in 12- or 24-hour extended release tablets and also includes the decongestant pseudoephedrine for powerful nasal congestion relief. CHILDREN'S CLARITIN(R) comes in great-tasting Grape Chewables or Syrup forms and is safe and effective for kids 2 and older.

Finally, CLARITIN Eye is an antihistamine eye drop found in the eye care aisle that works in minutes and relieves the itch of allergy eyes for up to 12 hours.

CLARITIN is the No. 1 physician-recommended and pediatrician-recommended non-drowsy over-the-counter allergy brand. The CLARITIN Rx-to-OTC switch in 2002 was the largest switch ever--and the first and only for a non-drowsy antihistamine. For more information on allergies and treatment, visit www.CLARITIN.com.

About Schering-Plough

Schering-Plough Consumer Health Care is the U.S. over-the-counter (OTC) and consumer products business unit of Schering-Plough an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

Liqui-Gels is a registered trademark of Catalent Pharma Solutions, Inc.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Approves Labeling Change for Non-Drowsy CLARITIN(R)
2. New Non-Drowsy CLARITIN(R) Liqui-Gels(R) Now Available
3. Scent To Sleep All Natural Non-Drowsy Sleep Mist Acquired by Innovative Custom Products, Inc. (ICP)
4. Claritin(R) Renews Sponsorship With Allergy Sufferer and NASCAR Star Carl Edwards
5. Photos: New CLARITIN(R) Eye Relieves Itchy Eyes For Up To 12 Hours
6. SCOLR Pharma, Inc. Submits Abbreviated New Drug Application for a 12-hour CDT-based Pseudoephedrine Formulation
7. Pollen, Fruits, Veggies Help Trigger Oral Allergy Syndrome
8. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
9. Clean to Ease Allergy and Asthma Symptoms
10. Mount Sinai & ENT and Allergy Associates, LLP affiliate to fight cancer
11. Allergists at Presbyterian Hospital of Dallas Say This Years Fall Allergy Season Could be Worst in Decades
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Via Oncology, the leading ... of a free, public-facing tool for analyzing the costs of various drug regimens ... comparative information to patients, providers, insurers and pharmaceutical companies about the estimated costs ...
(Date:3/28/2017)... DC (PRWEB) , ... March 28, 2017 , ... WHO: ... Dr. Toni Bark , WHAT: , Medical doctors and PhD scientists will speak to ... written to President Trump in support of an independent vaccine safety commission. , ...
(Date:3/28/2017)... ... 2017 , ... Calibration, qualification, and the appropriate level of ... GMP and USP compliance. In a new webinar from METTLER TOLEDO entitled “ ... requirements are explained. The challenge is to determine how to put the ...
(Date:3/28/2017)... Lithuania (PRWEB) , ... March 28, 2017 , ... ... technologies, today announced the release of two biometric time and attendance tracking products: ... Attendance 4.0 software. NCheck Cloud Bio Attendance uses biometric face recognition to ...
(Date:3/28/2017)... ... March 28, 2017 , ... In ... Self-Funding Success website has recently developed and published an informational resource that addresses ... created based on common inquiries the site’s team of third party administrator (TPA) ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... FinancialBuzz.com News Commentary  ... The U.S. could see significant economic benefits ... published by New Frontier Data, the legal cannabis market is projected ... legalization in the United States , as well ... a major factor that drives growth in this sector. Medical cannabis ...
(Date:3/28/2017)... 2017  Las Vegas ophthalmology practice, Center For Sight, ... (Allergan, Dublin ), an implant that ... reducing intraocular pressure in patients with moderate to severe ... by glaucoma that can lead to progressive optic nerve ... left untreated. According to the National Eye ...
(Date:3/28/2017)... LONDON , March 28, 2017 ... report,"Evolving Pharmaceutical Marketing Strategies: Digital as a Key ... of the changing pharmaceutical marketing landscape in the ... adopts new technologies to provide medical advancements, it ... its marketing efforts, mostly relying on traditional channels ...
Breaking Medicine Technology: